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Abstract
Thyroid honnone receptors (TRs) are nuclear receptors that are activated by
thyroid honnone ligands and co-regulator proteins. Two receptor subtypes, TRa and
TRB, have been identified and are implicated in numerous physiological functions.
However, due to the lack ofTR-specific ligands, full characterization of these receptors,
their specificity of function and specific mechanisms of action is largely unknown.
Therefore, bioassays that can identify TR-se1ective ligands are essential. A biochemical
assay was developed for the purpose of compound library screening and a cell-based
assay was developed to predict endogenous ligand-receptor specificity. Following assay
optimization, 5 known TR ligands were evaluated to characterize their selectivity and
interaction with the TR subtypes. In the biochemical assay, the rank order ofpotency
was similar in the presence of either SRCI-2 or NCoR, with T3 and Triac potencies
greater in the presence ofNCoR. The potency ofTetrac remained constant regardless of
co-regulator. The T4 and rT3 ligands demonstrated selectivity for TRa versus TRB
subtype. Conversely, in the cell-based assay all ligand potencies decreased and lacked
receptor selectivity, although the rank order potencies remained the same. The utility of
using both the biochemical and the cell-based assays in TR drug discovery will be
discussed.
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1. Introduction
Nuclear receptors (NRs) are a large family ofligand-activated transcription
factors that regulate the expression of target genes. The functionality ofNRs is
dependent on the ligand bound, as well as its interaction with components of
transcriptional machinery [1]. Typical ligands involved in activation ofNRs include
steroid and thyroid hormones, retinoids and vitamin D. Once the ligand is bound to the
NR, the NR and ligand complexes with additional factors, eventually binding to its
associated hormone response element which is located in the promoter region of the
target gene (Fig.I).
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Fig. 1. Ligand bound nuclear receptors (NR) translocate into the nucleus where they complex with co-
regulators and bind to its associated response element.
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This initiates transcriptional activation by transmitting signals to the basal transcriptional(
machinery, through protein-protein interactions. [2]. Chromatin facilitates the assembly
of this basal transcriptional machinery and increases the rate of transcription.
Nuclear receptor co-regulators are required for efficient transcriptional regulation.
These are cellular factors recruited by NRs that complement their function as mediators
of the cellular response to endocrine signals. Co-regulators are rate limiting for NR
activation and repression. Co-activators are molecules that enhance the transactivation of
nuclear receptors. Transactivation is an increased rate of gene expression triggered by
endogenous proteins. Conversely, co-repressors are factors that interact with NRs which
lower the transcription rate at their target genes [3]. It is hypothesized that NRs switch in
a ligand dependent manner, between binding a multi-component co-repressor and binding
a co-activator complex. The co-repressor complex contains histone deacetyltransferase
activity, while the co-activator complex contains histone acetyltransferase activity and is
further influenced by additional signal transduction pathways [4].
Thyroid hormone receptors (TR) are members of the NR superfamily that is
activated by the binding of thyroid hormones. The binding of the ligand causes
recruitment of the co-activator complexes that increase histone acetylation and recruit
RNA polymerase II to activate transcription [5]. The 3,5,3'-triiodothyronine (T3) ligand
is the most active form of thyroid hormone in target tissue. Activation or suppression of
TR affects numerous critical physiological processes including development, growth and
metabolism in higher organisms [6]. Investigation into the cause of cretinism and
myxedema, led to the discovery that these diseases were specifically due to the loss of
thyroid function. More importantly, this investigation led to the discovery ofT3 and L-
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thyroxine or T4, the most potent of the thyroid hormones [7]. The ligand T4 is a
prohormone which is metabolized to the active hormone T3 by either Type I 5'-
deiodinase or Type II 5'-deiodinase [8].
TR is encoded by two separate genes, TRa and TRp. The first subtype, TRa, was
originally cloned from chick embryo and mapped to human chromosome 17 [9]. The
TRp subtype was cloned from human placenta and found on chromosome 3 [10]. Each
subtype has multiple isoforms, TRa1, TRa2, TRa3 and TRpl and TRp2.
The primary function of a TR as a transcription factor, is to regulate target gene
expression directly through DNA response elements and more specifically the T3
response element (TRE). The TR ligand has the ability to bind TREs constitutively
independent ofligand occupancy. TRs bind TRE as heterodimers with retinoid X
receptor (RXR) (Fig. 2). This heterodimerization is thought to enhance the affinity of
__~~mm~__
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Fig. 2. Thyroid receptors (TR) heterodimerize with retinoid X receptor (RXR), enhancing binding ofTR
to the thyroid response element (TRE).
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NDNA binding and provide increased target gene specificity [11]. Distinct mechanisms
are used by the various isoforms to regulate this heterodimerization. However, when
ligand is bound, it initiates a conformational change in the TR, activating transcription of
its target gene. Conversely, an unliganded TR generally represses basal transcription.
The novelty to TR as well as all other liganded nuclear receptors, is that transcriptional
activation is mediated by co-activator and co-repressor protein interactions.
Many NRs, including TR, contain a highly conserved subregion within the
carboxy terminus ofthe ligand-binding domain (LBD). This region is necessary for
transcriptional activation and is termed activation function 2, or AF-2 region (Fig. 3) (4].
_AlB D_B_D__I_H_i_D_ge....I__L_B_D---.!_I_F 1 C
AF-l AF-2
Fig. 3. Nuclear receptors can be divided into six subregions. Region AlB contains the ligand independent
transactivation domain, AF-l. DBD is the DNA binding domain, followed by a hinge region which is part
of the LBD, or ligand binding domain. AF-2 is the ligand dependent transactivation domain, which is also
contained within the LBD.
Also, most NRs contain a non-conserved activation domain in the amino terminal
referred to as the AF-l region. This domain is highly divergent between the TRa and
TR~ isoforms, suggesting that these isoforms play different roles in transcriptional
regulation. Because this amino terminal domain is not required for T3-dependent
transcriptional activation by rat TR~l, it suggests that this domain may not be essential
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for TR function [11]. The AF-l domain functions to modulate both ligand-dependent
activation as well as ligand-independent interaction with co-repressors.
On the surface ofmost co-activators there is a highly conserved region referred to
as the LXXLL motif. These are helical domains with amphipathic characteristics. There
is a comparable motif in the AF-2 region ofNRs, suggesting that initial contact between
activated NRs and co-activators is highly reliant on this LXXLL motif. More
specifically, crystallographic evidence suggests that there is a ligand-dependent shift in
helix 12, a critical helix in the AF-2 region which creates a thermodynamically secure
environment for the LXXLL motif [4] [12].
The interaction ofTR and co-repressors, resides in a separate distinct region of
the LBD than that of receptor/co-activator interactions. The functionality of these co-
repressors is separate from the AF-2 domain. A core co-repressor complex contains more
than seven polypeptides, including the histone deacetylases referred to as HDACl and
HDAC2. It is suggested that these transcription factors that function as repressors,
employ a common mechanism involving the recruitment ofmulti-component complexes.
These complexes have histone deacetylase activity and re-establish a repressive
chromatin state, therefore, down-regulating basal transcription as chromatin plays an
important role in regulating the basal activity ofmany promoters.
To date, T3 has been almost exclusively used as the tool compound in identifying
the mechanism of action of thyroid hormones. However, derivatives ofT3 such as
triiodothyroacetic acid (TriAc), 3,3',5'-triiodothyronine (rT3), and also L-thyroxine, or
T4, and its derivative tetraiodothyroacetic acid (Tetrac), have not been evaluated for their
effects on TRa and TR~ in one assay format [13]. It is our intention to evaluate the
10
effects of these TR agonist compounds in combination with the co-activator peptide
SRCI-2 and the co-repressor peptide NCoR on both the TRa and TR~ subtypes.
SRC-l is a steroid receptor co-activator, the most common, that contains three
LXXLL motifs and is essential for T3 function. It has been found that mice without
functional SRC-l are T3 resistant [11]. The NCoR co-regulator is a co-repressor that has
two interaction sites. This correlates with the finding that two LBDs from two NRs are
required for functional interaction with co-repressors on DNA. The TRs have a CoR box
in the hinge region ofhelix 1 which is required for interaction with co-repressors.
A technology referred to as the AlphaScreen, is an association bioassay ideally
suited for studying co-recruitment. This bioassay employs glutathione-S-transferase
(OST) coated beads that complex with protein, ligand and co-peptide (Fig. 4).
Excitation
680nrn
.-.-.-.-._.- ......
.' ...... -....
Emission
520-620 nrn
Fig. 4. Thyroid hormone AlphaScreen biochemical assay. In the presence of ligand, the biotinylated co-
regulator, A, binds to the donor bead and fuses with the TR-LBD-GST, B, which is bound to the acceptor
bead. When brought into close proximity, these beads initiate a cascade of chemical reactions resulting in
the emission oflight at 520-620 nm.
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This assay was developed and utilized as the biochemical assay to investigate receptor,
ligand and co-regulator interactions. In this study, five compounds, T3, T4, Triac, Tetrac
and rT3, will be characterized using this assay. Additionally, a one hybrid cell-based
assay was developed and used to investigate the functional response of transiently
transfected COS-7 cells to these ligands and enable the ability to measure transactivation.
The intention of this study is to use a biochemical assay in conjunction with a cell-based
assay to evaluate data between assay platforms using 5 TR ligands. This will provide
insight into the functions of the TRs and the co-activators and co-repressors in the
presence ofvarious thyroid hormones and their ligand derivatives.
2. Materials and Methods
2.1. Chemicals and Reagents
The thyroid hormone agonists 3,5,3'-triiodothyronine (T3), triiodothyroacetic acid
(TriAc), 3,3',5'-triiodothyronine (rT3), L-thyroxine, (T4), and tetraiodothyroacetic acid
(Tetrac), were obtained from Sigma-Aldrich (St. Louis, MO). Dimethylsulfoxide
(DMSO) for compound dissolution, as well as bovine serum albumin (BSA) was also
obtained from Sigma-Aldrich (St. Louis, MO). The buffer components used in the
AlphaScreen included potassium chloride (KCI) and Tris, HCI, pH 8.0 which were
obtained from Invitrogen Corporation (Carlsbad, CA) and dithiothreitol (DTT) which
was obtained from Millipore (Billerica, MA). The TRa-LBD and TR~-LBD proteins
were obtained from Invitrogen Corporation (Carlsbad, CA). The steroid receptor co-
activator peptide (SRC1-2) and the nuclear receptor co-repressor peptide (NCoR) used in
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these studies were obtained from Anaspec (San Jose, CA). The Glutathione-S-
Transferase (GST) AlphaScreen beads were obtained from Perkin Elmer (Waltham, MA).
The Gateway pENTR1A vector used to make the constructs for transfection was
obtained from Invitrogen Corporation (Carlsbad, CA). The reagents used in the
transfection procedure included phenol red free (PRF) Dulbecco's Modified Eagle
Medium (DMEM), charcoal stripped fetal bovine serum, GlutaMAX, sQ.dium pyruvate
and Opti-MEM, were all obtained from Invitrogen Corporation (Carlsbad, CA).
FuGENE 6 was obtained from Roche Diagnostics Corporation (Indianapolis, IN) and the
luciferase cell culture lysis reagent for detection in the one-hybrid assay was obtained
from Promega (Madison, WI).
2.2. Cell Culture
The COS-7 cells, African green monkey kidney fibroblasts, (ATCC, Manassas,
VA) were cultured in DMEM with GlutaMAX, 10% heat inactivated fetal bovine serum
and 1% penicillin/streptomycin Invitrogen Corporation, Carlsbad, CA. The cells were
maintained at 37°C, 5% CO2 and passaged every 72 h at a ratio of 1mL of cell
suspension to 10 mL of media. On the day of transfection, the cells were resuspended at
100,000 cells per mL in PRF-DMEM containing 10% charcoal stripped fetal bovine
serum, 2 roM GlutaMax., and 1 roM sodium pyruvate. The cells were plated in 100 flL
aliquots, in a 96-well plate to reach a final cell density of 10,000 cells in each well.
13
SRC-l
2.3. Co-recruitment Assay
The AlphaScreen technology and methodology has been described previously
[14]. A modified version of these methods was optimized establishing the following
assay conditions: 5 nM purified GST labeled TRa-LBD (amino acid sequence 148-410)
or TR~-LBD (amino acid sequence 202-461), 10 nM SRCl-2 or NCoR biotinylated
peptide and a 1:250 dilution of Glutathione-S-Transferase AlphaScreen beads. The
combination of these components wi11later be referred to as the protein/bead/peptide
mixture. The sequences for SRCl-2 and NCoR peptides were Biotin-
HSSLTERHKILHRLLQEGSPSDITT (Fig. 5) and Biotin-
KKTHRLITLADHICQIITQDFARN, respectively (Anaspec, San Jose, CA).
, ...
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, ...
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Fig. 5. The co-activator peptide SRC-l contains three LXXLL binding motifs within the nuclear-receptor
interaction domain. The fragment of the SRC-l peptide that was used in the biochemical assay was the
SRCl-2 LXXLL binding motif.
The assay buffer contained 50 roM KCI, 50 roM Tris, pH 8.0, 2 roM DTT and 0.1 % BSA.
The plates used for this bioassay were 384-well Proxiplates (Perkin Elmer, Waltham,
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MA). In order to establish optimal assay conditions, appropriate protein concentrations
and incubations times were identified. In the experiments that were performed to
determine the optimal protein concentration, wells containing 1, 3, 5 and 10 nM of
protein were tested in the assay in the presence of the T3 ligand. In determining the
optimal incubation time, the assay conditions were run in the presence ofT3 at 1, 2, 4, 5
and 6 h.
Compounds were diluted using an 8-point serial dilution by halflog increments.
The starting concentration for T4, Tetrac and rT3 was 1 mM, while the starting
concentration for Triac and T3 was 10 IlM. The compound dilutions were made initially
in a Matrix 384-well polypropylene plate (Thermo Fisher Scientific, Hudson, NH), in
100% DMSO using the Biomek FX automated pipetting system (Beckman-Coulter,
Fullerton, CA). From the initial compound dilution plate, the compounds were
subsequently diluted lO-fold into 100% DMSO, followed by a 2.5-fold dilution into assay
buffer. These dilutions resulted in the highest concentrations ofT4, Tetrac and rT3 being
40 IlM and Triac and T3 being 400 nM. An aliquot of 5 ilL of the serially diluted
compounds was added to the Proxiplate, followed by an additional 5 ilL of assay buffer.
Finally, 10 ilL of the protein/beadJpeptide mixtures were added to the assay plate for a
total volume of20 ilL. The highest concentration in the serial dilution ofT4, Tetrac and
rT3 in the assay was 10 IlM whereas, the highest concentration ofTriac and T3 in the
assay was 100 nM. The final DMSO concentration was 9% DMSO in the assay. The
addition of the beads was done under green light as the GST-beads are light sensitive.
The plates were kept in the dark at room temperature for 2 h and were then counted on
the EnVision microplate analyzer (Perkin Elmer, Waltham, MA).
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2.4. One-Hybrid Cell-Based Assay
Constructs in which human TRa-LBD and TR~-LBD domains were cloned into
the Gateway pENTR1A vector (Invitrogen Corporation, Carlsbad, CA) were used. The
GAL4 DNA binding domain was incorporated into these constructs. The LBDs were of
the same amino acid sequences as those obtained from Invitrogen. COS-7 cells were
suspended at 100,000 cells/mL in culture media composed ofPRF-DMEM, 10% charcoal
stripped fetal bovine serum, 2 mM GlutaMAX and 1 mM Sodium Pyruvate. The cells
were then aliquoted in a 100 JlL volume into each well of a 96-well Polystyrene
CulturPlate (Perkin Eimer, Waltham, MA). This results in a final cell density of 10,000
cells per well. FuGENE 6 transfection reagent was used according to the supplier's
recommendations (Roche, Indianapolis, IN). This transfection methodology has been
previously described [15,16]with the following modifications. The GAL4/TR-LBD
plasmid and the Luciferase plasmid were added in a volume that equals approximately a
final concentration of 0.05 Jlg per well. The plate is then incubated at 37°C, 5% C02 for
5 h. Following transfection, compounds were serially diluted in 10% DMSO/media, with
starting concentrations for T3 and Triac being 100 JlM and rT3, Tetrac and T4 being 1
mM. Series of dilutions ofT3 and Triac starting at 10 JlM and rT3, Tetrac and T4,
starting at 100 JlM were added to the plate containing cells and media at a 1% DMSO
final concentration. The plates were incubated at 37°C, 5% C02, overnight, for
approximately 17 h. The following day, the media was removed and a 25 JlL aliquot of
lysis reagent was added to each well and the plate was placed on a shaker for 10 minutes
to lyse the cells. A 50 JlL aliquot of the luciferase assay reagent was added to each well,
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and the luciferase enzyme activity was measured using the Victor plate reader (Perkin.
Elmer, Waltham, MA).
2.5. Statistical Analysis
The ECso values, which represent halfof the maximal effective dose of the
compound, were detennined by using nonlinear regression sigmoidal dose response
analysis in SAS-Excel using the equation Y =Min+(Max-Min)/[1+exp(Hillx(log(ECso)-
10g(X)))]. The fold difference in the AlphaScreen was determined by dividing the
maximum counts per second (cps) values by the background cps values. The fold
difference in affinities of the compounds between the biochemical assay and the cell-
based assay was determined by dividing the ECso value in the cell-based assay by the
ECso value determined in the biochemical assay.
3. Results
3.1. Biochemical Assay Optimization
In order to optimize the AlphaScreen biochemical assay conditions for this study,
it was necessary to determine the optimal amount ofTRa. and TR~ protein as shown in
Fig. 6A and 6B. It was apparent that 1 nM ofprotein was an insufficient amount,
particularly when using TRa. protein. As 3 nM protein did demonstrate sufficient
efficacy, it may be the lower limit of acceptability as anything below this concentration
may compromise the consistency and reproducibility of the data. Therefore, SnM was
the protein concentration used in these studies.
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Fig. 6. Logistic concentration curves of the thyroid hormone T3 in the biochemical assay, using varying
amounts ofTRa protein (panel A) and TRp protein (Panel B).
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In addition, it was necessary to determine the appropriate incubation time for the
biochemical assay as demonstrated in Fig. 7A and 7B. Logistic concentration curves of
thyroid hormone T3 were tested using 5 nM ofboth the TRa and TR~ proteins.
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Fig. 7. Change in thyroid honnone T3 logistic concentration curves in the biochemical assay over time,
using 5 nM TRcx. protein (panel A) or TR~ protein (panel B).
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Each concentration curve was incubated for either 1, 2, 4, 5 or 6 h. The fold changes
were determined at each of these time points by dividing the total cps of each curve by
the background cps for each curve as seen in Tables lA and lB. From these results, it
was determined that 2h was the most suitable incubation time in that consistency in data
was observed and the length of the incubation is more amenable to compound screening.
Table lA. Determination of incubation time in the biochemical assay, using thyroid
hormone T3 and TRa protein.
Time (h) ECso's Total Background Fold
(nM±SEM) cps cps difference
1 1.0 ±0.12 68126 2102 32
2 1.0 ±0.07 104738 1405 75
4 0.98 ±0.10 162324 3729 44
5 0.91 ±0.15 175354 4048 43
6 0.91 ±-0.14 206775 3373 61
Graphic depiction oflogistic concentration curve (Fig. 6; Panel A)
T3, thyroid hormone.
TRa, thyroid hormone alpha receptor.
ECso values, concentrations that elicits half the maximal response ofT3.
Total cps, signal achieved in the presence of the maximum concentration ofT3, lOOnM.
Background cps, signal achieved in the presence of 9%DMSO in assay buffer.
Fold difference, total cps/background cps.
h, hours.
Table lB. Determination of incubation time in the biochemical assay, using thyroid
hormone T3 and TR~ protein.
Time (h) ECso's Total Background Fold
(nM±SEM) . cps cps difference
1 1.2 ±0.08 55190 1605 34
2 1.1 ±0.09 86929 1457 60
4 1.2 ±0.07 133656 2627 50
5 1.2 ±0.08 157444 3456 46
6 1.3 ±-0.09 185744 5197 36
Graphic depiction ofn logistic concentration curve (Fig. 6; Panel B)
T3, thyroid hormone.
TRp, thyroid hormone beta receptor.
ECso values, concentrations that elicits half the maximal response ofT3.
Total cps, signal achieved in the presence of the maximum concentration ofT3, lOOnM.
Background cps, signal achieved in the presence of 9%DMSO in assay buffer
Fold difference, total cpslbackground cps.
h, hours.
Finally, it was necessary to determine the maximum concentration ofDMSO that could
be tolerated in the biochemical assay. In order to do so, logistic concentration curves of
T3 were tested at varying concentrations ofDMSO. Data from 0% and 10% DMSO are
illustrated in Fig. 8. It was apparent that the biochemical assay could tolerate ligands
solubilized in up to 10% DMSO without compromising the integrity ofthe data.
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Fig. 8. Logistic concentration curves ofT3 demonstrating DMSO tolerability in the biochemical assay.
3.2. Biochemical Evaluation of Thyroid Hormone Ligands in the Presence of Co-
Regulators
Using these optimized conditions for the biochemical assay, the thyroid hormone
ligands T3, Triac, rT3, T4 and Tetrac were evaluated in logistic concentration curves
using TRa and TR~ proteins in the presence of co-activator peptide SRCI-2 and co-
repressor peptide NCoR. The concentration curves ofT3, T4 and rT3 in the presence of
the co-activator SRCI-2 are demonstrated in Fig. 9A, 9B and 9C respectively. The ECso
values for these ligands are illustrated in Table 2. All of the ligands, with the exception
ofTetrac, appeared slightly more potent at TRa than TR~. The order ofpotency ofthese
compounds for TRa from most potent to least was: Triac=T3>T4>Tetrac>rT3.
Interestingly, the order ofpotency of these compounds for TR~, from most potent to least
was: Triac=T3>Tetrac>T4>rT3.
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Fig. 9. Logistic concentration curves of thyroid hormones T3 (panel A), T4 (panel B) and rT3 (Pan~l C)
in the biochemical assay, using TRa and TRp in the presence of 10 nM SRCI-2 co-activator peptide.
Table 2. Potency and selectivity'of thyroid honnone receptor ligands in a biochemical
assay using either TRa or TR~ protein in the presence ofSRCl-2 co-activator peptide.
Ligand TRa TR~ Selectivity
ECso (nM ±SEM) ECso (nM ±SEM) (TR~/TRa.)
T3 0.77 ±0.06 1.2 ±0.10 1.6
Triac 0.74 ±0.07 1.1 ±0.14 1.5
rT3 57.1 ±9.80 176.3 ±25.4 I 3.1
T4 7.9 ±0.80 22.7 ±2.4 2.9
Tetrac 19.9 ±3.70 12.5 + 2.1 0.63
Graphical depiction of ligand logistic concentration response curves (Fig. 9; Panel A-C).
Data presented in the table were generated in a minimum of 2 separate assays done on different days. Each
test concentration was run in duplicate.
ECso values represent half the maximal effective concentration of ligand.
These five ligands were then evaluated in logistic concentration curves using TRa
and TR~ proteins in the presence of the co-repressor peptide NCoR. The concentration
curves ofT3, T4 and rT3 are demonstrated in Fig. lOA, lOB and lOC, respectively. The
ECso values for all of these ligands are illustrated in Table 3. The order ofpotency of
these ligands for TRa from most potent to least was: T3>Triac>T4>Tetrac>rT3. The
order ofpotency of these ligands for TR~, from most potent to least was: T3=Triac>
Tetrac>T4>rT3. Consistent with the SRCl-2 results, there is again a change in rank
order potency ofT4 and Tetrac between TRa than TR~. The rank order ofpotencies for
these compounds using both SRCl-2 and NCoR is similar to previously reported values
[17]. However, in this earlier report, Tetrac was not included in the studies.
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Fig. 10. Logistic concentration curves of thyroid hormones T3 (panel A), T4 (Panel B) and rT3 (panel C)
in the biochemical assay, using TRa and TR~ in the presence of 10 11M NCoR co-repressor peptide.
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Table 3. Potency and selectivity of thyroid honnone receptor ligands in a biochemical
assay using either TRa or TR~ protein in the presence of NCoR co-repressor peptide.
Ligand TRa TR~ Selectivity
ECso (nM ±SEM) ECso (nM ±SEM) (TR~/TRa)
T3 0.31 ± 0.07 0.44 ± 0.11 1.4
Triac 0.63 ± 0.11 0.58 ± 0.13 0.92
rT3 103.9 ± 19.2 423.5 ± 169 4.1
T4 9.2 ± 1.1 54.9 ± 11.5 6.0
Tetrac 19.5 ± 4.5 17.4±5.1 0.90
Graphical depiction oflogistic concentration response curves (Fig. 10; Panel A-C).
Data presented in the table were generated in a minimum of 2 separate assays done on different days. Each
test concentration was run in duplicate.
ECso values represent half the maximal effective concentration of ligand.
3.3. Evaluation of Thyroid Hormone Ligands in Cell-Based Assay
In order to compare the activity of these compounds in the biochemical assay and
a cell-based assay, they were evaluated in a One-Hybrid cell-based platfonn. It was first
necessary to determine the concentration ofDMSO tolerated in the cell-based assay.
Logistic concentration curves ofT3 were tested at varying concentrations ofDMSO as
seen in Fig~ 11. It was apparent that concentrations greater than 1% DMSO decreased
the overall cps signal, most likely due to cellular toxicity.
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Fig. 11. Logistic concentration response curves ofT3 demonstrating DMSO tolerability in the cell-based
assay.
After this was detennined, logistic concentration curves for T3, T4 and rT3 were tested as
seen in Fig. 12A, 12B and 12C, respectively. The ECso values for all of these ligands are
illustrated in Table 4. These ligands appeared less potent overall in the cell-based assay
than in the biochemical assay. However, the rank order ofpotency of these ligands were
the same for both TRa and TR~ in the cell-based assay. Most potent to least potent
being T3>TriaC>T4>Tetrac>rT3. It should be noted that the exact ECso values for rT3
are not reported as the dose response curves never reached a plateau at the higher
concentrations. This is most likely due to lack of complete solubility of the compound
because of the limiting DMSO concentration that is tolerated in this assay.
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Fig. 12. Logistic concentration curves of thyroid hormones T3 (Panel A), T4 (PIUlcl B) and rTJ (P:mc\
C), using TRa and TRp in the cell-based assay_
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Table 4. Potency and selectivity of thyroid hormone ligands in a cell-based assay using
either the TRa or TR~ protein.
Ligand TRa. TR~ Selectivity
ECso (nM ±SEM) ECso (nM ±SEM) (TR~/ TRa.)
T3 10.6 ± 2.0 11.8 ± 2.9 1.1
Triac 22.5 + 5.6 12.1 ± 4.2 0.54
rT3 ND ND ND
T4 417 ± 81 317 ± 55 0.76
Tetrac 824±176 493 ± 90 0.60
Graphical depiction ofligand logistic concentration curves (Fig. 12; Panel A-C).
Data presented in the table were generated in a minimum of 2 separate assays done on different days. Each
test concentration was run in triplicate.
ECso values represent half the maximal effective concentration of ligand.
ND, not determined due to non-logistic concentration response
3.4. Comparison of Thyroid Hormone Ligand Affmities in the Biochemical and Cell-
Based Assays
To demonstrate a direct comparison of the activities ofthese thyroid hormone
ligands in the biochemical and the cell-based assays, logistic concentration curves ofT3
at both TRa and TR~, are illustrated in Fig. 13A and 13B, respectively. It is apparent
that the potency ofT3 is significantly greater in the biochemical assay than in the cell-
based assay. The ECso values for all of the ligands in both assays as well as the fold
difference between the two values are reported in Tables 5A and 5B. The ECso values
for all of the ligands were more potent in the biochemical assay than in the cell-based
,
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assay for both TRa and TR~. However the fold differences when using the TRa protein
are greater between the assay platfonns than when using the TR~ protein.
A
C Biochemical Assay
~ Cell-based Assay
0, 1tD ......
-13 -12 -11 -10 -9 -8 -7 -6 -5
1'3 [M]
B
C Biochemical Assay
~ Cell-based Assay
O·LwI.........l.4I..~.........................1I..I.Il1IIII
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Fig. 13. Logistic concentration curves of thyroid hormone T3 at TRa (panel A) and TRp (Panel B)in the
biochemical versus cell-based assays.
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Table 5A. Comparison of ECso values ofthyroid honnone ligands between the cell-
based and biochemical assays using TRa protein.
Ligand Cell-based TRa-SRCl-2 TRa.-NCoR
Bioassay Biochemical Biochemical
ECso (nM ±SEM) Bioassay Bioassay
ECso (nM ±SEM) ECso (nM ±SEM)
[Fold Difference] [Fold Difference]
T3 10.6 ± 2.0 0.77 ± 0.06 [13.8] 0.31 ± 0.07 [34.2]
Triac 22.5 ± 5.6 0.74 ± 0.07 [30.4] 0.63 ± 0.11 [35.7]
rT3 ND 57.1 ± 9.80 [ND] 103.9 ± 19.2 [ND]
T4 417 ± 81 7.9 ± 0.80 [52.8] 9.2 ± 1.1 [45.3]
Tetrac 824±176 19.9 ± 3.70 [41.4] 19.5 ± 4.5 [42.3]
ECso values represent half the maximal effective concentration of ligand.
Fold difference is determined by dividing the less potent of the two ECso values of a given ligand generated
between assays, by the more potent ECso value.
ND, not determined due to non-logistic concentration response.
Table 5B. Comparison of ECso values ofthyroid h6nnone ligands between the cell-
based and biochemical assays using TR~ protein.
Ligand Cell-based Bioassay TR~-SRCl-2 TR~-NCoR
ECso (nM ±SEM) Biochemical Biochemical
Bioassay Bioassay
ECso (nM ±SEM) ECso (nM ±SEM)
[Fold Difference] [Fold Difference]
T3 11.8 ± 2.9 1.2 ± 0.10 [9.8] 0:44 ± 0.11 [26.8]
Triac 12.1 ± 4.2 1.1±O.14 [11] 0.58 ± 0.13 [20.9]
rT3 ND 176.3 ± 25.4 [ND] 423.5 ± 169 [ND]
T4 317 ± 55 22.7 +2.4 [14] 54.9 ± 11.5 [5.8]
Tetrac 493 ± 90 12.5 ± 2.1 [39.4] 17.4 ± 5.1 [28.3]
ECso values represent half the maximal effective concentration of ligand.
Fold difference is determined by dividing the less potent of the two ECso values of a given ligand generated
between assays, by the more potent ECso value.
ND, not determined due to non-logistic concentration response.
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4. Discussion
Thyroid honnone receptors have been reported to affect numerous critical
physiological processes and are activated or repressed by the binding of thyroid honnone.
[6]. The two receptor subtypes ofTR, TRa and TRp, are of scientific interest as they
have been implicated in a variety of disorders [11]. However, due to the lack ofTR
specific ligands, full characterization of these receptors, their specificity of function, and
their specific mechanisms of action are largely unknown. Therefore, development of
bioassays that can be used to identify new TR-selective ligands are essential in order to
further elucidate the role of the TR subtypes in physiology. Thus, a biochemical assay
was developed for the purposes of compound library screening and for the assessment of
co-regulator interactions. In addition, a cell-based assay was developed that can be used
in conjunction with the biochemical assay to more accurately predict endogenous and
exogenous ligand specificity and receptor interaction. Following the optimization and
development of these two bioassays, 5 known TR ligands were evaluated in parallel in
these assays to characterize their potency and selective interaction with the TR subtypes.
The biochemical assay was developed using the AlphaScreen technology. The
AlphaScreen platfonn was selected because it is suitable for high-throughput screening
and amenable to studying co-regulator interactions. Assay optimization using both
receptor subtypes was completed and the optimal protein concentrations, kinetic
parameters and ligand carrier (tolerability) were detennined. Because most compounds
are soluble in DMSO, and this assay will be primarily used for compound screening,
DMSO was chosen as the ligand dissolution carrier. The optimal protein concentration
for both the TRa and TRP-LBD was 5 nM at a 2 h (25°C) incubation time. It was
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detennined that this assay could tolerate up to a 10% final DMSO concentration without
compromising the maximum signal or affinity value achieved for T3 at either receptor
subtype. The fold difference between the maximum signal and the background was
typically greater than 40-fold in this assay. Similar experiments were conducted in order
to optimize the cell-based assay. In the cell-based assay, it was detennined that the
optimal plating density of cells in the assay was 10,000 cells per well. The assay was
perfonned at 37°C, 5% C02, and allowed to incubate overnight. The maximum
percentage ofDMSO tolerated in the cell-based assay was 1% final concentration, which
consistently'a!lowed for approximately 20-fold difference between maximum and
background signal for T3 at both receptor subtypes.
After completion of assay optimization, the 5 TR ligands were evaluated in the
biochemical assay for TRa or TR~ in the presence of either the SRCI-2 co-activator or
NCoR co-repressor peptide fragments. In the presence of SRCl-2, the rank order of
potency between subtypes was different due to the reduced potency ofT4 in the TR~
assay. The rank order ofpotency was T3=Triac> T4>Tetrac>rT3 in the TRa assay,
whereas it was T3=Triac>Tetrac>T4>rT3 in the TR~ assay (Table 2). The T3 and Triac
ligands demonstrated similar or equal potencies at both receptor subtypes, however the
T4ligand showed a 3-fold higher potency for TRa when compared to the potency noted
for this ligand in the TR~ assay. The least potent ligand at both subtypes was the rT3
ligand, which, due to deiodinization at the tyrosyl ring, is essentially an inactive fonn of
T4 known to have lower affinity for nuclear receptors [8]. Although this rT3 ligand
showed similar rank order placement regardless ofwhich receptor subtype was present, it
did demonstrate a 3-fold increased selectivity for the TRa subtype. These data suggest
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that based on the ligand structure, modest selectivity for a specific receptor subtype can
be achieved in the presence of the SRCl-2 peptide. In the presence of the NCoR co-
repressor peptide, the rank order of the ligands between subtypes was similar to the rank
order affinities noted in the presence of the SRCl-2 peptide. The rank order ofpotency
was T3>Triac> T4>Tetrac>rT3 in the TRu assay, whereas it was
T3=Triac>Tetrac>T4>rT3 in the TRp assay (Table 3). The T3 ligand demonstrated the
highest potency overall when in the presence ofNCoR peptide. Additionally, both the T4
and rT3 ligands maintained their selectivity for TRu that was noted in the presence of the
SRCl-2 peptide. The rT3 ligand showed the lowest potency overall regardless of
receptor subtype or co-regulator used.
In comparing the ligand potency differences in the presence of the two co-
regulators, T3 and Triac demonstrated the highest potency in the presence ofNCoR
regardless of receptor subtype. It should be noted that in the presence ofNCoR, the
potency for the ligand is dependent on the ability of these ligands to dissociate the co-
repressor peptide. Conversely, in the presence of SRCl-2, the ligand potency is
dependent on the ability of the ligand/ receptor complex to recruit the co-activator
peptide [17]. The dissociation or recruitment of the co-regulator is directly influenced by
the conformation of the receptor in the presence of the ligand. Moreover, the co-
regulator interaction with the receptor for the ligand/receptor complex can influence the
affinity of the ligand, as well as determine the functional consequence of the binding
------interaction[18]. Interestingly, it was observed that the potency ofTetrac was not affected
regardless of the co-regulator present or the receptor subtype. Tetrac is a deamination
product ofT4 and has been shown to block thyroid hormone binding, but has no agonist
'i4
activity at the hormone receptor site [19]. These results indicate that the binding of
Tetrac to the ligand binding domains ofTRa and TRB induces a conformation which is
equally conducive to co-repressor dissociation and co-activator recruitment. In addition,
these data may reflect the involvement of the non-agonist characteristics ofTetrac that
have been reported [20]. It is imperative to use caution when interpreting the data
derived in the biochemical assay. The biochemical assay is a very simplistic bioassay
that is designed to allow for screening large compound libraries. The co-regulators used
in this assay are only peptide fragments of the full-length co-regulators that are expressed
endogenously. The ratio of the receptor to the co-regulator is critical and will determine
functional consequence of the interaction. In the biochemical assay the receptor and co-
regulator content is kept constant, therefore, this ratio may not directly translate to the
receptor/co-regulator ratios found in various cell lines or tissues. Also, only 2 of the
known TR co-regulators were evaluated in the biochemical assay. Therefore, the higher
affinity noted for T3 in the presence ofNCoR, the selectivity ofrT3 and T4 for TRa, and
the lack of affinity differences with Tetrac regardless of co-regulator or receptor subtype
may not be representative when evaluating these ligands in cell-based or tissue
preparations. Thus, the importance ofevaluating these ligands in a cell line that can
express the ligand binding domain and all full-length TR co-regulators is critically
important to assure the findings will translate endogenously. Therefore, a cell-based
assay was developed using the COS-7 cells. These cells were selected because they are
easily transfectable with the TR subtypes. Overall, the potencies ofthe ligands tested
were reduced when compared to the data generated from the biochemical assay. This
shift may be due to the fact that the full complement of co-regulators are present, and the
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change in potency may be a result of the occurrence of some repression counteracting the
activation of the receptors. More importantly, there was no selectivity noted between the
subtypes for either T4 or rT3 that was previously demonstrated in the biochemical assay.
In fact, for the rT3 ligand, the potency shift was significant enough that the
concentrations necessary to produce a complete concentration curve were too high to
maintain the ligand in solution at the maximum percentage ofDMSO tolerated in this
assay. Therefore, these concentration-response curves did not reach plateau, prohibiting
the estimation of an accurate ECso value.
Taken together, the major pharmacological difference noted between the
biochemical and the cell-based assay was the lack of selectivity translation in the cell-
based assay that was shown by T4 and rT3 for TRa in the biochemical assay. Also, an
overall reduced potency for the ligands was noted in the cell-based assay when compared
with the biochemical assay. However, as the potencies of the ligands were reduced in the
cell-based assay, the rank order of the ligands remained similar. Ultimately, in trying to
understand or establish a pharmacological profile ofthese ligands or any experimental
compound, the cell-based assay would be most relevant. The cell-based assay provides
the endogenous make-up of the co-regulators that are critically involved in receptor-
mediated function and are present in various varieties and densities in different tissues.
Therefore, the potency as well as the selectivity for any given compound will be tissue
context-dependent. However, this fact should not minimize the importance of the
biochemical assay. The development of such an assay allows for accelerated screening of
a large number ofcompounds as well as an overall rank ordering of compound affinity
for a given receptor subtype. In addition, the biochemical assay may provide important
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information for chemical structure modification that may lead to compounds that are
receptor-selective in both biochemical and cell-based assays.
5. Conclusion
From this study, it was made apparent that the affinity of thyroid hormone ligands
and their derivatives, for TRa and TRp is dependent on not only the assay platform, but
also the co-regulator present. However, the rank order ofpotencies of the thyroid
hormone ligands, regardless of which co-regulator was present, remained similar.
Interestingly, there was a change in rank order ofpotencies between the TRa and TRp
subtypes for the T4 and Tetrac ligands. This could provide further insight into the
binding ofligands to TR receptor subtypes. Also, it was noted that the ligands T4 and
rT3 demonstrated selectivity in the biochemical assay but not in the cell-based assay.
This further emphasizes the distinction between assay formats, but more specifically a
distinction between the interaction of thyroid hormone ligands with TRa and TRp in a
synthetic environment as opposed to one that is more representative of a naturally
occurring environment.
In summary, a biochemical and cell-based assay was developed and optimized in
order to characterize known TR ligands at both TRa and TRp subtypes and to further
understand their interactions. Our findings provide an initial assessment of these ligands
for the TR subtypes as well as the influence of2 co-regulators on the ligand-receptor
interaction. This information will be used to further explore the receptor subtype
differences and undertake a medicinal chemistry effort to develop small molecule
17
agonists and antagonists that will discriminate between the 2 receptor subtypes and allow
for further understanding of their role in the physiology ofTR biology.
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